On the stock market since 2020, it operates in the world of health and science. It has 32 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $173.4M in the vault; even if every debt were paid off, $169.5M would remain.
The average analyst price target is $7.75 — 169% above today’s price.
A loss of $22.2M against $0 in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, IMAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMAB is a high-risk stock — not yet profitable, and its future rides on its product catching on.